The Clinton Administration's Mixed Messages On Biomedical Research And Innovation

In his eloquent speech, the president said reform should "strengthen what is good about our health-care system--the world's best health-care professionals, cutting edge research, and wonderful research institutions." I agree. The United States is the world leader in biomedical research and innovation. At a breathtaking pace, our scientists and laboratories produce new drugs, medical devices, and surgical techniques that prolong and

Written byJohn Clymer
| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

In his eloquent speech, the president said reform should "strengthen what is good about our health-care system--the world's best health-care professionals, cutting edge research, and wonderful research institutions." I agree.

The United States is the world leader in biomedical research and innovation. At a breathtaking pace, our scientists and laboratories produce new drugs, medical devices, and surgical techniques that prolong and improve human life and reduce the cost of health care. When these new drugs, devices, and techniques enable people to remain productive instead of becoming disabled, our country's economic well- being improves; and when these same innovations replace older, more costly treatments, quality health care becomes more affordable for all.

Unfortunately, many suggested health-care "reforms" would diminish medical innovation. Some policymakers, including the White House health-care task force, have recommended de facto price controls on breakthrough drugs. However, economists--liberals and conservatives alike--agree that price controls don't work. When government ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies